Literature DB >> 10647617

Biodistribution, dosimetry, and safety of myocardial perfusion imaging agent 99mTcN-NOET in healthy volunteers.

G Vanzetto1, D Fagret, R Pasqualini, J P Mathieu, F Chossat, J Machecourt.   

Abstract

UNLABELLED: 99mTcN-NOET (bis[N-ethoxy,N-ethyl]dithiocarbamato nitrido technetium (V)) has been proposed for myocardial perfusion imaging. Biodistribution, safety, and dosimetry were studied in 10 healthy volunteers (5 at rest and 5 during exercise).
METHODS: Biodistribution was studied by acquiring dynamic images up to 60 min after injection and whole-body images up to 24 h after injection. The MIRDOSE3 analysis program was used for radiation dosimetry calculations.
RESULTS: Safety parameters measured to 48 h after injection revealed no clinically significant changes. Cardiac uptake of 99mTcN-NOET was high (2.9%-3%), with biologic half-life of 210-257 min on average. Lung uptake of 99mTcN-NOET was higher (10%-20%) but, on average, biologic half-life was shorter (1-77 min). Clearance from the blood was rapid (5% by 5 min). Radiation dosimetry calculations indicated an effective absorbed dose of 5.11 x 10(-3) mSv/MBq at rest and 5.38 x 10(-3) mSv/MBq after exercise.
CONCLUSION: 99mTcN-NOET exhibits high cardiac uptake and an estimated effective absorbed dose comparable with that of the other 99mTc-labeled compounds used in myocardial perfusion imaging.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10647617

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

Review 1.  Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: technical, physiologic, and clinical issues.

Authors:  P Kailasnath; A J Sinusas
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

2.  Tc-99m N-NOET: Chronicle of a unique perfusion imaging agent and a missed opportunity?

Authors:  Gérald Vanzetto; Daniel Fagret; Catherine Ghezzi
Journal:  J Nucl Cardiol       Date:  2004 Nov-Dec       Impact factor: 5.952

3.  EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology.

Authors:  B Hesse; K Tägil; A Cuocolo; C Anagnostopoulos; M Bardiés; J Bax; F Bengel; E Busemann Sokole; G Davies; M Dondi; L Edenbrandt; P Franken; A Kjaer; J Knuuti; M Lassmann; M Ljungberg; C Marcassa; P Y Marie; F McKiddie; M O'Connor; E Prvulovich; R Underwood; B van Eck-Smit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

4.  Comparison between Tc-99m N-NOET and Tl-201 in the assessment of patients with known or suspected coronary artery disease.

Authors:  Paramjit Jeetley; Nikant K Sabharwal; Prem Soman; Chris Kinsey; Usha Raval; Uday Bhonsle; Avijit Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Nov-Dec       Impact factor: 5.952

5.  Assessment of non-reperfused and reperfused myocardial infarction using diffusible or deposited radiolabelled perfusion imaging agents.

Authors:  L M Riou; A Broisat; C Lartizien; M C Toufektsian; S Maitrejean; M Janier; G Vanzetto; D Fagret; C Ghezzi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-27       Impact factor: 9.236

Review 6.  Technetium-99m Radiopharmaceuticals for Ideal Myocardial Perfusion Imaging: Lost and Found Opportunities.

Authors:  Alessandra Boschi; Licia Uccelli; Lorenza Marvelli; Corrado Cittanti; Melchiore Giganti; Petra Martini
Journal:  Molecules       Date:  2022-02-10       Impact factor: 4.411

7.  The in vivo cardiac kinetics of Tc-99m N-NOET are accelerated in obese, hyperlipidemic Zucker rats.

Authors:  Laurent M Riou; Alexis Broisat; Julien Dimastromatteo; Gérald Vanzetto; Daniel Fagret; Catherine Ghezzi
Journal:  J Nucl Cardiol       Date:  2006 Jan-Feb       Impact factor: 5.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.